Physician profile
Joshua Lowinsky
NPI 1689625493
$3,813.56
in general payments reported to CMS, 2019-2025
27 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $103 · 2021: $142 · 2022: $407 · 2023: $152 · 2024: $1,257 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $910.21 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $380.03 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $352.53 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $322.17 | 2022-2025 | |
| Axsome Therapeutics, INC. | $256.28 | 2024-2025 | Auvelity, Sunosi |
| Corium, LLC | $205.71 | 2021-2025 | Azstarys |
| Lundbeck LLC | $162.81 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $150.91 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $150.16 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $140.53 | 2019-2025 | Spravato |
| Noven Therapeutics, LLC | $128.76 | 2024-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $92.57 | 2019-2024 | |
| Neos Therapeutics, LP | $90.68 | 2019-2025 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.01 | 2022-2024 | Caplyta |
| Collegium Pharmaceutical, INC. | $48.38 | 2025 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $46.25 | 2020-2025 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $42.53 | 2024-2025 | Relexxii |
| Neurocrine Biosciences, INC. | $42.33 | 2019-2022 | |
| Allergan, INC. | $31.83 | 2019-2020 | |
| Adlon Therapeutics L.P. | $30.65 | 2019 | |
| Neuronetics, INC. | $24.75 | 2024 | Neurostar Tms Therapy System |
| Shire North American Group INC | $23.77 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.87 | 2019 | |
| Owp Pharmaceuticals, INC. | $19.80 | 2024 | Subvenite |
| Rhodes Pharmaceuticals L.P. | $18.12 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Novo Nordisk INC | $14.36 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Lowinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.